Lauren Levitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren Levitz has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Anne Searls De Groot
EpiVax, Inc, Providence, USA
4 shared publications K Tounkara
GAIA Vaccine Foundation, Bamako, Mali
4 shared publicationsAs De Groot
GAIA Vaccine Foundation, Bamako, Mali
3 shared publications- Leonard Moise
EpiVax, Inc., Providence, RI, USA
3 shared publications M Rochas
GAIA Vaccine Foundation, Bamako, Mali
3 shared publicationsO Koita
University of Bamako, Bamako, Mali
3 shared publications
Latest Publications
- Open Access
- 13 December 2015
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 213 (9) , 1491-1494
MicroscopicPlasmodium falciparumGametocytemia and Infectivity to Mosquitoes in Cambodia
Although gametocytes are essential for malaria transmission, in Africa many falciparum-infected persons without smear-detectable gametocytes still infect mosquitoes. To see whether the same is true in Southeast Asia, we determined the infectiousness of 119 falciparum-infected Cambodian adults to Anopheles dirus mosquitoes by membrane feeding. Just 5.9% of subjects infected mosquitoes. The 8.4% of patients with smear-detectable gametocytes were >20 times more likely to infect mosquitoes than those without and were the source of 96% of all mosquito infections. In low-transmission settings, targeting transmission-blocking interventions to those with microscopic gametocytemia may have an outsized effect on malaria control and elimination.
- 13 December 2015
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 213 (9) , 1491-1494
Open AccessMicroscopicPlasmodium falciparumGametocytemia and Infectivity to Mosquitoes in Cambodia
Although gametocytes are essential for malaria transmission, in Africa many falciparum-infected persons without smear-detectable gametocytes still infect mosquitoes. To see whether the same is true in Southeast Asia, we determined the infectiousness of 119 falciparum-infected Cambodian adults to Anopheles dirus mosquitoes by membrane feeding. Just 5.9% of subjects infected mosquitoes. The 8.4% of patients with smear-detectable gametocytes were >20 times more likely to infect mosquitoes than those without and were the source of 96% of all mosquito infections. In low-transmission settings, targeting transmission-blocking interventions to those with microscopic gametocytemia may have an outsized effect on malaria control and elimination.
- Open Access
- 12 April 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (7) , 1555-1557
Report from the field
The Sixth Annual Vaccine Renaissance Conference, hosted by the Institute for Immunology and Informatics (iCubed) at the University of Rhode Island (URI), took place on October 15–17, 2012. This conference provides a forum for the review of current progress in the discovery and development of vaccines, and creates an environment for the exchange of ideas. Dr. Joel McCleary opened the conference with a warning about the importance of preparing for well-defined biowarfare threats, including tularemia and Staphylococcal enterotoxin B. Following the keynote address, sessions explored biodefense and preparation for pandemic and biowarfare threats; vaccines for emerging and re-emerging neglected tropical diseases; animal vaccines and human health; and vaccine vectors and the human microbiome. In this issue of Human Vaccines and Immunotherapeutics, seven Vaccine Renaissance Conference speakers will showcase their work; here, we describe a few of the conference highlights.
- 12 April 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 9 (7) , 1555-1557
Open AccessReport from the field
The Sixth Annual Vaccine Renaissance Conference, hosted by the Institute for Immunology and Informatics (iCubed) at the University of Rhode Island (URI), took place on October 15–17, 2012. This conference provides a forum for the review of current progress in the discovery and development of vaccines, and creates an environment for the exchange of ideas. Dr. Joel McCleary opened the conference with a warning about the importance of preparing for well-defined biowarfare threats, including tularemia and Staphylococcal enterotoxin B. Following the keynote address, sessions explored biodefense and preparation for pandemic and biowarfare threats; vaccines for emerging and re-emerging neglected tropical diseases; animal vaccines and human health; and vaccine vectors and the human microbiome. In this issue of Human Vaccines and Immunotherapeutics, seven Vaccine Renaissance Conference speakers will showcase their work; here, we describe a few of the conference highlights.
- Open Access
- 19 February 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56402
A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali
Despite a high prevalence of oncogenic human papilloma virus (HPV) infection and cervical cancer mortality, HPV vaccination is not currently available in Mali. Knowledge of HPV and cervical cancer in Mali, and thereby vaccine readiness, may be limited. Research staff visited homes in a radial pattern from a central location to recruit adolescent females and males aged 12–17 years and men and women aged ≥18 years (N = 51) in a peri-urban village of Bamako, Mali. Participants took part in structured interviews assessing knowledge, attitudes, and practices related to HPV, cervical cancer, and HPV vaccination. We found low levels of HPV and cervical cancer knowledge. While only 2.0% of respondents knew that HPV is a sexually transmitted infection (STI), 100% said they would be willing to receive HPV vaccination and would like the HPV vaccine to be available in Mali. Moreover, 74.5% said they would vaccinate their child(ren) against HPV. Men were found to have significantly greater autonomy in the decision to vaccinate themselves than women and adolescents (p = 0.005), a potential barrier to be addressed by immunization campaigns. HPV vaccination would be highly acceptable if the vaccine became widely available in Bamako, Mali. This study demonstrates the need for a significant investment in health education if truly informed consent is to be obtained for HPV vaccination. Potential HPV vaccination campaigns should provide more information about HPV and the vaccine. Barriers to vaccination, including the significantly lower ability of the majority of the target population to autonomously decide to get vaccinated, must also be addressed in future HPV vaccine campaigns.
- 19 February 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e56402
Open AccessA Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali
Despite a high prevalence of oncogenic human papilloma virus (HPV) infection and cervical cancer mortality, HPV vaccination is not currently available in Mali. Knowledge of HPV and cervical cancer in Mali, and thereby vaccine readiness, may be limited. Research staff visited homes in a radial pattern from a central location to recruit adolescent females and males aged 12–17 years and men and women aged ≥18 years (N = 51) in a peri-urban village of Bamako, Mali. Participants took part in structured interviews assessing knowledge, attitudes, and practices related to HPV, cervical cancer, and HPV vaccination. We found low levels of HPV and cervical cancer knowledge. While only 2.0% of respondents knew that HPV is a sexually transmitted infection (STI), 100% said they would be willing to receive HPV vaccination and would like the HPV vaccine to be available in Mali. Moreover, 74.5% said they would vaccinate their child(ren) against HPV. Men were found to have significantly greater autonomy in the decision to vaccinate themselves than women and adolescents (p = 0.005), a potential barrier to be addressed by immunization campaigns. HPV vaccination would be highly acceptable if the vaccine became widely available in Bamako, Mali. This study demonstrates the need for a significant investment in health education if truly informed consent is to be obtained for HPV vaccination. Potential HPV vaccination campaigns should provide more information about HPV and the vaccine. Barriers to vaccination, including the significantly lower ability of the majority of the target population to autonomously decide to get vaccinated, must also be addressed in future HPV vaccine campaigns.
- Open Access
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (2) , P295
Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (2) , P295
Open AccessFurther confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
- Open Access
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (2) , P294
Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (2) , P294
Open AccessConservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
- Open Access
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (S2) , P230
Pediatric HIV infection due to maternal transmission: a solvable problem in a peri-urban setting in Bamako, Mali
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (S2) , P230
Open AccessPediatric HIV infection due to maternal transmission: a solvable problem in a peri-urban setting in Bamako, Mali
- Open Access
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (S2) , P128
Evaluating short-term patient outcomes after HIV care interventions in a low resource setting: preparing for an HIV vaccine trial site in Bamako, Mali
- 13 September 2012
- Published by Springer Nature in Retrovirology
- Vol. 9 (S2) , P128
Open AccessEvaluating short-term patient outcomes after HIV care interventions in a low resource setting: preparing for an HIV vaccine trial site in Bamako, Mali
- 1 July 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (7) , 987-1000
Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes
Two major obstacles confronting HIV vaccine design have been the extensive viral diversity of HIV-1 globally and viral evolution driven by escape from CD8+ cytotoxic T-cell lymphocyte (CTL)-mediated immune pressure. Regions of the viral genome that are not able to escape immune response and that are conserved in sequence and across time may represent the “Achilles’ heel” of HIV and would be excellent candidates for vaccine development. In this study, T-cell epitopes were selected using immunoinformatics tools, combining HLA-A3 binding predictions with relative sequence conservation in the context of global HIV evolution. Twenty-seven HLA-A3 epitopes were chosen from an analysis performed in 2003 on 10,803 HIV-1 sequences, and additional sequences were selected in 2009 based on an expanded set of 43,822 sequences. These epitopes were tested in vitro for HLA binding and for immunogenicity with PBMCs of HIV-infected donors from Providence, Rhode Island. Validation of these HLA-A3 epitopes conserved across time, clades, and geography supports the hypothesis that epitopes such as these would be candidates for inclusion in our globally relevant GAIA HIV vaccine constructs.
- 1 July 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (7) , 987-1000
Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes
Two major obstacles confronting HIV vaccine design have been the extensive viral diversity of HIV-1 globally and viral evolution driven by escape from CD8+ cytotoxic T-cell lymphocyte (CTL)-mediated immune pressure. Regions of the viral genome that are not able to escape immune response and that are conserved in sequence and across time may represent the “Achilles’ heel” of HIV and would be excellent candidates for vaccine development. In this study, T-cell epitopes were selected using immunoinformatics tools, combining HLA-A3 binding predictions with relative sequence conservation in the context of global HIV evolution. Twenty-seven HLA-A3 epitopes were chosen from an analysis performed in 2003 on 10,803 HIV-1 sequences, and additional sequences were selected in 2009 based on an expanded set of 43,822 sequences. These epitopes were tested in vitro for HLA binding and for immunogenicity with PBMCs of HIV-infected donors from Providence, Rhode Island. Validation of these HLA-A3 epitopes conserved across time, clades, and geography supports the hypothesis that epitopes such as these would be candidates for inclusion in our globally relevant GAIA HIV vaccine constructs.